In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus

Molecular Medicine Reports

Volumn 2, Issue 3, 2009, Pages 399-403

  Holle, Lori ^a   Song, Wen ^a   Holle, Eric ^a   Nilsson, Jennifer ^a   Wei, Yangzhang ^a,b   Li, Jinhua ^a   Wagner, Thomas E ^a,b   Yu, Xianzhong ^a,b  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Amoebapore; Cytolytic peptides; Prostate cancer

Indexed keywords

AMOEBAPORE HELIX 3 PEPTIDE; ANTINEOPLASTIC AGENT; GLUTAMIC ACID; HYBRID PROTEIN; IODINE 125; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE TUMOR; PROTEIN DOMAIN; PROTEIN MODIFICATION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR CELL DESTRUCTION; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

MUS; MUS MUSCULUS;

EID: 69249093854     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000112     Document Type: Article

References (14)

1. Espey DK, Wu XC, Swan J, et al: Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110: 2119-2152, 2007.
2. Crawford ED, Rosenblum M, Ziada AM and Lange PH: Hormone refractory prostate cancer. Urology 54: 1-7, 1999.
3. DeFeo-Jones D, Garsky VM, Wong BK, et al: A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6: 1248-1252, 2000.
4. DeFeo-Jones D, Brady SF, Feng DM, et al: A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol Cancer Ther 1: 451-459, 2002.
5. Brady SF, Pawluczyk JM, Lumma PK, et al: Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J Med Chem 45: 4706-4715, 2002.
6. Wong BK, DeFeo-Jones D, Jones RE, et al: PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 29: 313-318, 2001.
7. Warren P, Li L, Song W, Holle E, Wei Y, Wagner T and Yu X: In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res 61: 6783-6787, 2001.
8. Chandran SS, Nan A, Rosen DM, Ghandehari H and Denmeade SR: A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther 6: 2928-2937, 2007. (Pubitemid 350206771)
9. Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C and Drevs J: Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Archiv der Pharmazie 338: 462-472, 2005. (Pubitemid 41564256)
10. Schmid B, Chung D, Warnecke A, Fichtner I and Kratz F: Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 18: 702-716, 2007. (Pubitemid 47010789)
11. Chung DE and Kratz F: Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg Med Chem Lett 16: 5157-5163, 2006.
12. Warnecke A, Fichtner I, Garmann D, Jaehde U and Kratz F: Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjug Chem 15: 1349-1359, 2004. (Pubitemid 39552025)
13. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT and Denmeade SR: A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99: 376-385, 2007. (Pubitemid 47073481)
14. Kline T, Torgov MY, Mendelsohn BA, Cerveny CG and Senter PD: Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharmacol 1: 9-22, 2004.